https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/ gsk.com
https://www.gsk.com/en-gb/media/press-releases/gsk-to-showcase-long-term-outcomes-and-pipeline-expansion-with-latest-oncology-research-at-asco-and-eha/ gsk.com
https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-receives-expanded-approval-in-japan-for-adults-aged-18-59-at-increased-risk/ gsk.com
https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-collaboration-with-sbp-group-a-market-leader-in-hepatology-in-china-to-accelerate-bepirovirsen-at-launch/ gsk.com
https://www.gsk.com/en-gb/media/press-releases/gsk-presents-latest-respiratory-research-to-advance-patient-care-at-ats-2026/ gsk.com
https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q1-performance-and-start-to-2026/ gsk.com
https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-priority-review-and-granted-breakthrough-therapy-designation-by-the-us-fda/ gsk.com
https://www.gsk.com/en-gb/media/press-releases/gsk-s-investigational-liver-therapy-efimosfermin-receives-us-fda-breakthrough-therapy/ gsk.com
https://www.gsk.com/en-gb/media/press-releases/tesaro-a-gsk-subsidiary-provides-update-on-anaptysbio-inc-litigation/ gsk.com
https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-approved-in-china-for-treatment-of-2lplus-relapsedrefractory-multiple-myeloma/ gsk.com
